The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?

References

• Azoulay P. Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy (2002) 11(4):551–594Crossref, Google Scholar
• Becker G., Murphy K. A simple theory of advertising as a good or bad. Quart. J. Econom. (1993) 108(4):941–963Crossref, Google Scholar
• Berndt E. R., Bui L. T., Reiley D. H., Urban G. L. Information, marketing and pricing in the U.S. anti-ulcer drug market. Amer. Econom. Rev. (1995) 85(2):100–105Google Scholar
• Calabro S. In DTC-free Europe, just as many patients ask for brand drugs. Medical Marketing Media (2003) 38(11):30Google Scholar
• Chew L. D., O'Young T. S., Hazlet T. K., Bradley K. A., Maynard C., Lessler D. S. A physician survey of the effect of drug sample availability on physicians' behavior. J. General Internal Medicine (2000) 15(July):478–483Crossref, Google Scholar
• Chintagunta P. K., Desiraju R. Strategic pricing and detailing behavior in international markets. Marketing Sci. (2005) 24(1):67–80Link, Google Scholar
• Dong X., Manchanda P., Chintagunta P. K. Quantifying the benefits of individual level targeting in the presence of firm strategic behavior. (2005) . Working paper, University of Chicago, Chicago, ILGoogle Scholar
• Duffy C. M., Clark M., Hiris J. Who receives free sample medications? J. General Internal Medicine (2003) 18(April):205Google Scholar
• Economist, The Survey: Devil in the detail. (2005) June 18):9Google Scholar
• Edwards J. News analysis: Turf war escalates over big pharma marketing. Brandweek (2005) 46(40):6Google Scholar
• Franses P. H. On the use of econometric models for policy simulation in marketing. J. Marketing Res. (2005) 42(1):4–14Crossref, Google Scholar
• Gönül F. F., Carter F., Petrova E., Srinivasan K. Promotion of prescription drugs and its impact on physicians' choice behavior. J. Marketing (2001) 65(3):79–90Crossref, Google Scholar
• Grossman G., Shapiro C. Informative advertising with differentiated products. Rev. Econom. Stud. (1984) 51(1):63–81Crossref, Google Scholar
• Hradecky G. Backlash against the number of reps in the field could change the sales model forever. Pharmaceutical Representative (2004) April 1Google Scholar
• Hollon M. F. Direct-to-consumer advertising: A haphazard approach to health promotion. J. Amer. Medical Assoc. (2005) 293(16):2030–2032Crossref, Google Scholar
• Janakiraman R., Dutta S., Sismeiro C., Stern P. Are they all the same? Physicians' persistence and its implications for marketing communication. (2005) . Working paper, University of Southern California, Los Angeles, CAGoogle Scholar
• Kravitz R. L., Bell R. A., Azari R., Kelly-Reif S., Krupat E., Thom D. H. Direct observation of requests for clinical services in office practice: What do patients want and do they get it? Arch. Internal Medicine (2003) 163(14):1673–1681Crossref, Google Scholar
• Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R., Wilkes M. S., Hinton L., Franks P. Influence of patients' requests for direct-to-consumer advertised antidepressants. J. Amer. Medical Assoc. (2005) 293(16):1995–2002Crossref, Google Scholar
• Leeflang P., Wieringa J., Wittink D. The effects of pharmaceutical marketing on sales of prescription drugs in the Netherlands. Sixth CU-Boulder Invitational Choice Sympos. (2004) Estes Park, COGoogle Scholar
• Leffler K. B. Persuasion or information? The economics of prescription drug advertising. J. Law Econom. (1981) 24(1):45–74Crossref, Google Scholar
• Lyles Alan. Direct marketing of pharmaceuticals to consumers. Ann. Rev. Public Health (2002) 23:73–91Crossref, Google Scholar
• Manchanda P., Chintagunta P. K. Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett. (2004) 15(2–3):129–145Crossref, Google Scholar
• Manchanda P., Rossi P. E., Chintagunta P. K. Response modeling with nonrandom marketing-mix variables. J. Marketing Res. (2004) 41(November):467–478Crossref, Google Scholar
• Mintzes B., Barer M. L., Kravitz R. L., Bassett B., Lexchin J., Kazanjian A., Evans R. G., Pan R., Marion S. A. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association J. (2003) 169(5):405–412Google Scholar
• Mizik N., Jacobson R. Are physicians “easy marks?” Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. (2004) 50(12):1704–1715Link, Google Scholar
• Morelli D., Koenigsberg M. R. Sample medication dispensing in a residency practice. J. Family Practice (1992) 34(1):42–48Google Scholar
• Narayanan S., Manchanda P. Heterogeneous learning and the targeting of marketing communication for new products. (2004) . Working paper, Graduate School of Business, Stanford University, Stanford, CAGoogle Scholar
• Narayanan S., Manchanda P. The role of free samples in the pharmaceutical industry: An empirical analysis. 2006 INFORMS Marketing Sci. Conf. (2006) University of Pittsburgh, Pittsburgh, PAGoogle Scholar
• Narayanan S., Desiraju R., Chintagunta P. K. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. J. Marketing (2004) 68(4):90–105Crossref, Google Scholar
• Narayanan S., Manchanda P., Chintagunta P. K. Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. (2005) 42(3):278–290Crossref, Google Scholar
• Neslin S. Analysis of ROI for pharmaceutical promotion. (2001) . Unpublished study conducted for the Association of Medical Publications, http://www.rxpromoroi.org/arpp/index.htmlGoogle Scholar
• Parsons L. J., Vanden Abeele P. Analysis of sales call effectiveness. J. Marketing Res. (1981) 18(1):107–113Crossref, Google Scholar
• Rizzo J. A. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J. Law Econom. (1999) 42(1):89–116Crossref, Google Scholar
• Rosenthal M. B., Berndt E. R., Donohue J. M., Epstein A. M., Frank R. G., Cutler D. M., Garber A. M. Demand effects of recent changes in prescription drug information. Frontiers in Health Policy Research (2003) 6(MIT Press, Cambridge, MA) 1–26Google Scholar
• Tanner M. A., Wong W. H. The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. (1987) 82(398):528–549Crossref, Google Scholar
• Wall Street Journal, The Merck withheld Vioxx safety information, plaintiff's lawyer claims. (2006) March 7):D4Google Scholar
• Weissman J. S., Blumenthal D., Silk A. J., Newman M., Zapert K., Leitman R., Feibelmann S. Physician report on patient encounters involving direct-to-consumer advertising. Health Affairs (2004) April 28):W4/219–W4/233Google Scholar
• Wilkes M. S., Bell R. A., Kravitz R. L. Direct-to-consumer prescription drug advertising: Trends, impact and implications. Health Affairs (2000) 19(2):110–128Crossref, Google Scholar